Doctors test new drug combo in battle against aggressive blood cancer
NCT ID NCT05558124
Summary
This early-stage study aims to find the safest and most effective dose when combining two chemotherapy drugs, CPX-351 and gemtuzumab ozogamicin, to treat newly diagnosed acute myeloid leukemia (AML). Researchers will enroll up to 18 adult patients to test different dose levels and monitor how well the combination works against the cancer while tracking side effects. The goal is to gather enough safety data to recommend a dose for larger future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.